Filing Flows › Health Care › GSK (GSK)
GSK (GSK) earnings and revenue breakdown
Latest: Q3 2026 · 6-K filed Oct 28, 2026 · GSK (GSK) Q3 2026 earnings results →
Q3 2026 24¢ of every $1 of revenue kept as net profit · operating margin 30.3%
GSK made $8.5B in Q3 2026: Specialty Medicines $3.9B, Dolutegravir products $1.4B, Dovato $754M. Operating margin 30.3%, net earnings $2.0B. See where every dollar goes — costs, profit and cash — as a Sankey from the 6-K filed Oct 28, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was £8.5B in Q3 2026, up 2% from the previous quarter. HIV was the largest line at 25% of revenue.
Gross margin was 73.6%. Operating profit was £2.6B, a 30.3% margin. Net earnings were £2.0B. The effective tax rate was 12.7%.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 6-K | Oct 28, 2026 | $8.5B | — | 30.3% | $2.0B | — |
| Q2 2026 | 6-K | Sep 8, 2026 | $8.4B | +5% | 5.7% | $435M | — |
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
GSK against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: 30.3% against the peers' median 30.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GSK GSK | Q3 2026 | $11.5B | — | 30.3% |
| NVO Novo Nordisk A S | FY2025 | $46.8B | +6% | 41.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| SNY Sanofi | Q3 2026 | $16.6B | +16% | 30.1% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| NVS Novartis AG | Q3 2026 | $14.5B | +4% | 12.7% |
Source: GSK 6-K on SEC EDGAR · CIK 1131399 · Pharmaceutical Preparations
13F: who owns GSK and who is buying
More on GSK
History
Every quarter: Q3 2026 results · Q2 2026 results